Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: DiaMedica Therapeutics Inc.

Market Cap 425M 304M 262M 241M 226M 28.74B 429M 2.85B 1.11B 14.07B 1.14B 1.12B 48.7B P/E Ratio 2026 *
-6.81x
P/E Ratio 2027 * -6.42x
Enterprise Value 425M 304M 262M 241M 226M 28.74B 429M 2.85B 1.11B 14.07B 1.14B 1.12B 48.7B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
56.7%
Yield 2026 *
-
Yield 2027 * -
1 day-0.35%
1 week+0.36%
Current month-6.01%
1 month-7.10%
3 months-21.59%
6 months-35.06%
Current year-29.27%
1 week 5.24
Extreme 5.245
5.9
1 month 5.24
Extreme 5.245
6.44
Current year 5.24
Extreme 5.245
9.04
1 year 3.48
Extreme 3.475
10.42
3 years 1.94
Extreme 1.9382
10.42
5 years 1.12
Extreme 1.12
10.42
10 years 1.12
Extreme 1.12
13.77
Manager TitleAgeSince
Chief Executive Officer 54 2009-12-31
Director of Finance/CFO 60 2018-03-31
Chief Tech/Sci/R&D Officer 60 2025-08-10
Director TitleAgeSince
Director/Board Member 70 2010-08-09
Chairman 54 2008-03-31
Chairman 60 2024-12-31
Date Insider Type Main position Quantity % Market Cap.
05-31Option

Chief Executive Officer

380,000 0.7052%
05-31Option

Director

40,412 0.0750%
05-31Option

Chairman

51,189 0.0950%
Change 5-day change 1-year change 3-year change Capi.($)
-0.35%+0.36%+60.40%+77.04% 304M
-2.86%-0.63%+51.45%+109.01% 56.42B
-0.34%+2.91%+45.55%+46.87% 44.54B
+0.29%+6.20%-14.61%-19.65% 22.9B
-0.40%+3.49%-4.07%+387.06% 21.21B
-0.51%-5.56%+10.43%-29.97% 16.4B
-1.54%+0.66%+7.63%-40.19% 15.4B
-0.24%+2.44%+26.95%+177.49% 13.35B
+0.96%+6.56%+20.81% - 12.36B
+0.32%+1.60%+96.37%+207.56% 11.15B
Average -0.47%+1.51%+30.09%+101.69% 21.4B
Weighted average by Cap. -0.93%+2.54%+30.42%+97.16%

Financials

2026 *2027 *
Net sales - -
Net income -63.21M -45.22M -38.97M -35.87M -33.65M -4.27B -63.84M -424M -166M -2.09B -170M -166M -7.24B -78.02M -55.82M -48.11M -44.28M -41.54M -5.28B -78.8M -523M -204M -2.58B -209M -205M -8.94B
Net Debt - -
Logo DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on improving the lives of people suffering from preeclampsia (PE) and acute ischemic stroke (AIS). The Company’s lead candidate, DM199, is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of pre-eclampsia, acute ischemic stroke and other vascular diseases. DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1 (rhKLK1) in clinical development for preeclampsia and acute ischemic stroke. KLK1 is a serine protease enzyme that is involved in the regulation of diverse physiological processes via a molecular mechanism that increases the production of nitric oxide, prostacyclin and endothelium-derived hyperpolarizing factors. In the treatment of preeclampsia, DM199 is intended to lower blood pressure, enhance endothelial health and improve perfusion to maternal organs and the placenta.
Employees
35
Date Price Change Volume
26-06-15 5.630 $ -0.35% 185,767
26-06-12 5.650 $ +3.48% 105,015
26-06-11 5.460 $ +2.44% 148,688
26-06-10 5.330 $ -1.66% 155,860
26-06-09 5.420 $ -3.39% 351,393
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
5.650USD
Average target price
15.50USD
Spread / Average Target
+174.34%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. DMAC Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!